| GELF17 |
| All of the following: |
| Maximum diameter of disease < 7 cm |
| Fewer than 3 nodal sites |
| No systemic symptoms |
| Spleen < 16 cm on CT |
| No significant effusions |
| No risk of local compressive symptoms |
| No circulating lymphoma cells |
| No marrow compromise (Hb < 10 g/dL, WBC count < 1.5 × 109/L, platelet count < 100 × 109/L) |
| BNLI18 |
| None of the following: |
| B symptoms or pruritus |
| Rapid generalized disease progression |
| Marrow compromise (Hb ≤ 10 g/dL, WBC count < 3.0 × 109/L, or platelet count < 100 × 109/L) |
| Life-threatening organ involvement |
| Renal infiltration |
| Bone lesions |
| GELF17 |
| All of the following: |
| Maximum diameter of disease < 7 cm |
| Fewer than 3 nodal sites |
| No systemic symptoms |
| Spleen < 16 cm on CT |
| No significant effusions |
| No risk of local compressive symptoms |
| No circulating lymphoma cells |
| No marrow compromise (Hb < 10 g/dL, WBC count < 1.5 × 109/L, platelet count < 100 × 109/L) |
| BNLI18 |
| None of the following: |
| B symptoms or pruritus |
| Rapid generalized disease progression |
| Marrow compromise (Hb ≤ 10 g/dL, WBC count < 3.0 × 109/L, or platelet count < 100 × 109/L) |
| Life-threatening organ involvement |
| Renal infiltration |
| Bone lesions |
To convert Hb from grams per deciliter to grams per liter, multiply grams per deciliter by 10.
GELF indicates Groupe pour l'Etude de Lymphome Folliculaire; Hb, hemoglobin level; WBC, white blood cell; BNLI, British National Lymphoma Investigation.